期刊文献+

动脉粥样硬化中的表观遗传机制及治疗作用

Research of epigenetics in the regulation mechanisms and treatment roles of atherosclerosis
下载PDF
导出
摘要 动脉粥样硬化(atherosclerosis, As)的发展过程与炎症反应、脂质代谢紊乱以及环境等因素密切相关。表观遗传的研究主要涉及DNA甲基化、非编码RNA调控、组蛋白修饰和染色质重塑等调节机制。越来越多的研究揭示表观遗传参与了As的发生发展。表观遗传的异常变化在介导泡沫细胞产生、内皮功能障碍、血管平滑肌细胞(vascular smooth muscle cell,VSMC)表型转换等方面发挥着关键作用。文章对表观遗传在As中的调控机制和治疗作用进行阐述,并总结其最新研究进展,旨在从非遗传因素角度为临床As的早期诊断和个性化治疗提供参考。 The development of atherosclerosis(As)is closely related to inflammatory response,lipid metabolism disorders and environmental factors.Epigenetic studies are concerned with regulatory mechanisms such as DNA methylation,non-coding RNA regulation,histone modifications and chromatin remodeling.An increasing number of studies have revealed the involvement of epigenetics in the development of As.Aberrant epigenetic changes play a key role in mediating foam cell production,endothelial dysfunction,and vascular smooth muscle cell(VSMC)phenotype transformation.In this paper,we describe the regulatory mechanisms and therapeutic roles of epigenetics in As,and summarize the latest research progress,aiming to provide a reference for early diagnosis and personalized treatments of clinical As from the perspective of non-genetic factors.
作者 童晓岚 宋佳欣 姜继宗 TONG Xiaoan;SONG Jiaxin;JIANG Jizong(Shanghai Engineering Research Center of Organ Repair,School of Medicine,Shanghai University,Shanghai 200444,China;School of Life Sciences,Shanghai University,Shanghai 200444,China)
出处 《自然杂志》 CAS 2024年第1期73-82,共10页 Chinese Journal of Nature
基金 上海市2022年度“科技创新行动计划”自然科学基金面上项目(22ZR1423100)。
关键词 表观遗传 DNA甲基化 组蛋白修饰 非编码RNA 动脉粥样硬化 epigenetics DNA methylation histone modification non-coding RNA atherosclerosis
  • 相关文献

参考文献3

二级参考文献30

  • 1LAN Fei1 & SHI Yang 2 1 Department of Biology, Constellation Pharmaceuticals, 148 Sidney Street, Cambridge, MA 02139, USA 2 Department of Pathology, Harvard Medical School, 77 Ave Louise Pasteur, Boston MA, 02115, USA.Epigenetic regulation: methylation of histone and non-histone proteins[J].Science China(Life Sciences),2009,52(4):311-322. 被引量:27
  • 2Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin Ⅱ- mediated cardiovascular and renal diseases, Pharmacol Rev 2000; 52: 11-34.
  • 3Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin Ⅱ in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERKand p38 MAPK but not for JNK. J Biol Chem 2001; 276: 7957-62.
  • 4Gao D, Niu X, Ning N, Hao G. kruppel-like factor 5 expression Pharm Bull 2006: 29: 2004-8.
  • 5Regulation of angiotensin Ⅱ-induced n vascular smooth muscle cells. Biol Schmitz U, Ishida T, Ishida M, Surapisitchat J, Hasham MI, Pelech S, et al. Angiotensin Ⅱ stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. Circ Res 1998; 82: 1272-8.
  • 6Kusuhara M, Takahashi E, Peterson TE, Abe J, Ishida M, Han J, et al. p38 Kinase is a negative regulator of angiotensin Ⅱ signal transduction in vascular smooth muscle cells: effects on Na^+/H^+ exchange and ERK1/2. Circ Res 1998; 83: 824-31.
  • 7Suzuki T, Muto S, Miyamoto S, Aizawa K, Horikoshi M, Nagai R. Functional interaction of the DNA-binding transcription factor Spl through its DNA-binding domain with the histone chaperone TAF-1. J Biol Chem 2003; 278: 28758-64.
  • 8Bateman NW, Tan D, Pestell RG, Black JD, Black AR. Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem 2004; 279: 12093-101.
  • 9Nandan MO, Chanchevalap S, Dalton WB, Yang VW. Kruppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation. FEBS Lett 2005; 579: 4757-62.
  • 10Nandan MO, Yoon HS, Zhao W, Ouko LA, Chanchevalap S, Yang VW. Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene 2004; 23: 3404-13.

共引文献220

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部